Lifileucel plus Pembrolizumab — Competitive Intelligence Brief

Lifileucel plus Pembrolizumab (Lifileucel plus Pembrolizumab) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Autologous cell therapy combined with PD-1 inhibitor. Area: Oncology.

phase 3 Autologous cell therapy combined with PD-1 inhibitor PD-1 (pembrolizumab component); tumor-associated antigens (lifileucel component) Oncology Biologic

Target snapshot

Lifileucel plus Pembrolizumab (Lifileucel plus Pembrolizumab) — Iovance Biotherapeutics, Inc.. Lifileucel is an autologous tumor-infiltrating lymphocyte (TIL) therapy that expands patient-derived T cells from their tumor and reinfuses them alongside pembrolizumab, a PD-1 inhibitor, to enhance anti-tumor immune response.

Comparator set

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Lifileucel plus Pembrolizumab TARGET	Lifileucel plus Pembrolizumab	Iovance Biotherapeutics, Inc.	phase 3	Autologous cell therapy combined with PD-1 inhibitor	PD-1 (pembrolizumab component); tumor-associated antigens (lifileucel component)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Autologous cell therapy combined with PD-1 inhibitor class)

1. Iovance Biotherapeutics, Inc. · 1 drug in this class